| Variables | Overall (n = 27) | Functional capacity | OR (95% CI) | P value | |
| Impaired (n = 8) | Normal (n = 19) | ||||
| Male, n (%) | 8 (29.6) | 3 (37.5) | 5 (26.3) | 1.7 (0.3 - 9.7) | 0.658 |
| Age (yrs), Mean ± SD | 53.2 ± 14.4 | 56.8 ± 16.4 | 51.6 ± 13.6 | - | 0.409 |
| Urban environment, n (%) | 21 (77.8) | 3 (37.5) | 18 (94.7) | 0.03 (0.003 - 0.4) | 0.004 |
| VTE risk factors, n (%) |
|
|
|
|
|
| Orthopaedic surgery | 1 (3.7) | 0 (0) | 1 (5.3) | - | 1.000 |
| Post-partum | 1 (3.7) | 0 (0) | 1 (5.3) | - | 1.000 |
| Bed rest | 2 (7.4) | 0 (0) | 2 (10.5) | - | 1.000 |
| Long distance travel | 6 (22.2) | 3 (37.5) | 3 (15.8) | 3.2 (0.5 - 21.2) | 0.319 |
| HIV infection | 2 (7.4) | 0 (0) | 2 (10.5) | - | 1.000 |
| COVID-19 infection | 2 (7.4) | 1 (12.5) | 1 (5.3) | 2.6 (0.1 - 47.01) | 0.513 |
| Past history of VTE | 2 (7.4) | 0 (0) | 2 (10.5) | - | 1.000 |
| Hypertension | 11 (40.7) | 3 (37.5) | 8 (42.1) | 0.8 (0.2 - 4.5) | 1.000 |
| Smoking | 3 (11.1) | 2 (25) | 1 (5.3) | 6.0 (0.5 - 78.6) | 0.201 |
| Diabetes | 6 (22.2) | 2 (25) | 4 (21.1) | 1.3 (0.2 - 8.7) | 1.000 |
| Thromboembolic heart disease | 6 (22.2) | 3 (37.5) | 3 (15.8) | 3.2 (0.5 - 21.2) | 0.319 |
| Clinical signs, n (%) |
|
|
|
|
|
| Syncope | 5 (18.5) | 4 (50) | 1 (5.3) | 18 (1.6 - 207.4) | 0.017 |
| Thoracic pain | 14 (51.9) | 4 (50) | 10 (52.6) | 0.9 (0.2 - 4.7) | 1.000 |
| Dyspnoea | 21 (77.8) | 6 (75) | 15 (78.9) | 0.8 (0.1 - 5.6) | 1.000 |
| Cough | 3 (11.1) | 1 (12.5) | 2 (10.5) | 1.2 (0.09 - 15.7) | 1.000 |
| Haemoptysis | 3 (11.1) | 1 (12.5) | 2 (10.5) | 1.2 (0.09 - 15.7) | 1.000 |
| Gallop | 1 (3.7) | 1 (12.5) | 0 (0) | - | 0.296 |
| Lower limb pain | 10 (37) | 4 (50) | 6 (31.6) | 2.2 (0.4 - 11.7) | 0.415 |
| Lower limbs oedema | 11 (40.7) | 4 (50) | 7 (36.8) | 1.7 (0.3 - 9.1) | 0.675 |
| Homan’s sign | 9 (33.3) | 2 (25) | 7 (36.8) | 0.6 (0.09 - 3.6) | 0.676 |
| Obesity | 9 (33.3) | 7 (87.5) | 2 (10.5) | 59.5 (4.6 - 767.2) | <0.001 |